# Efficacy and Safety of Therapy With IgM-enriched Immunoglobulin With a Personalized Dose vs Standard Dose in Patients With Septic Shock.

> **NCT04182737** · PHASE3 · UNKNOWN · sponsor: **Massimo Girardis** · enrollment: 356 (estimated)

## Conditions studied

- Shock, Septic
- Sepsis
- Hypoglobulinemia

## Interventions

- **DRUG:** IgM-enriched polyclonal immunoglobulins titer-based treatment
- **DRUG:** IgM-enriched polyclonal immunoglobulins Flat treatment

## Key facts

- **NCT ID:** NCT04182737
- **Lead sponsor:** Massimo Girardis
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-01
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-03-31
- **Target enrollment:** 356 (ESTIMATED)
- **Last updated:** 2021-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04182737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04182737, "Efficacy and Safety of Therapy With IgM-enriched Immunoglobulin With a Personalized Dose vs Standard Dose in Patients With Septic Shock.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04182737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*